2obu
From Proteopedia
| Line 1: | Line 1: | ||
| - | [[Image:2obu.gif|left|200px]] | + | [[Image:2obu.gif|left|200px]] |
| - | + | ||
| - | '''Solution structure of GIP in TFE/water''' | + | {{Structure |
| + | |PDB= 2obu |SIZE=350|CAPTION= <scene name='initialview01'>2obu</scene> | ||
| + | |SITE= | ||
| + | |LIGAND= | ||
| + | |ACTIVITY= | ||
| + | |GENE= | ||
| + | }} | ||
| + | |||
| + | '''Solution structure of GIP in TFE/water''' | ||
| + | |||
==Overview== | ==Overview== | ||
| Line 10: | Line 19: | ||
==About this Structure== | ==About this Structure== | ||
| - | 2OBU is a [ | + | 2OBU is a [[Single protein]] structure of sequence from [http://en.wikipedia.org/wiki/ ]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2OBU OCA]. |
==Reference== | ==Reference== | ||
| - | The bioactive conformation of glucose-dependent insulinotropic polypeptide by NMR and CD spectroscopy., Alana I, Malthouse JP, O'Harte FP, Hewage CM, Proteins. 2007 Jul 1;68(1):92-9. PMID:[http:// | + | The bioactive conformation of glucose-dependent insulinotropic polypeptide by NMR and CD spectroscopy., Alana I, Malthouse JP, O'Harte FP, Hewage CM, Proteins. 2007 Jul 1;68(1):92-9. PMID:[http://www.ncbi.nlm.nih.gov/pubmed/17393464 17393464] |
[[Category: Single protein]] | [[Category: Single protein]] | ||
[[Category: Alana, I.]] | [[Category: Alana, I.]] | ||
| Line 21: | Line 30: | ||
[[Category: gip; nmr; molecular modelling; helix; diabetes; obesity]] | [[Category: gip; nmr; molecular modelling; helix; diabetes; obesity]] | ||
| - | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu | + | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Mar 20 17:57:39 2008'' |
Revision as of 15:57, 20 March 2008
| |||||||
| Coordinates: | save as pdb, mmCIF, xml | ||||||
Solution structure of GIP in TFE/water
Contents |
Overview
Glucose-dependent insulinotropic polypeptide (GIP) is a gastrointestinal incretin hormone, which modulates physiological insulin secretion. Because of its glucose-sensitive insulinotropic activity, there has been a considerable interest in utilizing the hormone as a potential treatment for type 2 diabetes. Structural parameters obtained from NMR spectroscopy combined with molecular modeling techniques play a vital role in the design of new therapeutic drugs. Therefore, to understand the structural requirements for the biological activity of GIP, the solution structure of GIP was investigated by circular dichroism (CD) followed by proton nuclear magnetic resonance (NMR) spectroscopy. CD studies showed an increase in the helical character of the peptide with increasing concentration of trifluoroethanol (TFE) up to 50%. Therefore, the solution structure of GIP in 50% TFE was determined. It was found that there was an alpha-helix between residues 6 and 29, which tends to extend further up to residue 36. The implications of the C-terminal extended helical segment in the inhibitory properties of GIP on gastric acid secretion are discussed. It is shown that the adoption by GIP of an alpha-helical secondary structure is a requirement for its biological activity. Knowledge of the solution structure of GIP will help in the understanding of how the peptide interacts with its receptor and aids in the design of new therapeutic agents useful for the treatment of diabetes.
Disease
Known diseases associated with this structure: Pituitary ACTH-secreting adenoma OMIM:[139360], Ventricular tachycardia, idiopathic OMIM:[139360]
About this Structure
2OBU is a Single protein structure of sequence from [1]. Full crystallographic information is available from OCA.
Reference
The bioactive conformation of glucose-dependent insulinotropic polypeptide by NMR and CD spectroscopy., Alana I, Malthouse JP, O'Harte FP, Hewage CM, Proteins. 2007 Jul 1;68(1):92-9. PMID:17393464
Page seeded by OCA on Thu Mar 20 17:57:39 2008
